Human leukocyte antigen Bw4 and Bw6 epitopes recognized by antibodies and natural killer cells

Current Opinion in Organ Transplantation

Volumn 19, Issue 4, 2014, Pages 436-441

  Lutz, Charles T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antibody; Bw4; Bw6; Human leukocyte antigen epitope; KIR3DL1

Indexed keywords

HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN; HLA B ANTIGEN; HLA BW4 ANTIGEN; HLA BW6 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; EPITOPE; HLA-BW4 ANTIGEN; HLA-BW6 ANTIGEN;

ALLELE; ALLOTYPE; ALPHA HELIX; AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; BINDING AFFINITY; CYTOTOXICITY; GRAFT REJECTION; HUMAN; NATURAL KILLER CELL; NONHUMAN; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; REVIEW; SITE DIRECTED MUTAGENESIS; IMMUNOLOGY;

ANTIBODIES; EPITOPES; HLA-B ANTIGENS; HUMANS; KILLER CELLS, NATURAL;

EID: 84904198750     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000103     Document Type: Review

References (37)

1. Van Rood JJ, van Leeuwen A. Leukocyte grouping. A method and its application. J Clin Invest 1963; 42:1382-1390.
2. Müller CA, Engler-Blum G, Gekeler V, et al. Genetic and serological heterogeneity of the supertypic HLA-B locus specificities Bw4 and Bw6. Immunogenetics 1989; 30:200-207.
3. Lutz CT, Smith KD, Greazel NS, et al. Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the a-1 helix. J Immunol 1994; 153:4099-4110.
4. Kosmoliaptsis V, Dafforn TR, Chaudhry AN, et al. High-resolution, threedimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011; 72:1049-1059.
5. Novotny J, Bruccoleri RE, Saul FA. On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3 and HyHEL-5. Biochemistry 1989; 28:4735-4749.
6. Amit AG, Mariuzza RA, Phillips SEV, Poljak RJ. Three-dimensional structure of an antigen-antibody complex at 2.8A resolution. Science 1986; 233:747-753.
7. El-Awar N, Terasaki PI, Nguyen A, et al. New HLA class I epitopes defined by murine monoclonal antibodies. Hum Immunol 2010; 71:456-461.
8. Marrari M, Mostecki J, Mulder A, et al. Human monoclonal antibody reactivity with human leukocyte antigen class I epitopes defined by pairs of mismatched eplets and self-eplets. Transplantation 2010; 90:1468-1472.
9. + B*27:05 patient. Transplantation ; In press.
10. Fineberg SE, Galloway JA, Fineberg NS, Goldman J. Effects of species of origin, purification levels, and formulation on insulin immunogenicity. Diabetes 1983; 32:592-599.
11. Kuhner MK, Lawlor DA, Ennis PD, Parham P. Gene conversion in the evolution of the human and chimpanzee MHC class I loci. Tissue Antigens 1991; 38:152-164.
12. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268:405-408.
13. Wagtmann N, Biassoni R, Cantoni C, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995; 2:439-449.
14. Long EO, Wagtmann N. Natural killer cell receptors. Curr Opin Immunol 1997; 9:344-350.
15. Long EO, Kim HS, Liu D, et al. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-258.
16. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342.
17. Cella M, Longo A, Ferrara GB, et al. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994; 180:1235-1242.
18. Luque I, Solana R, Galiani DM, et al. Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones. Eur J Immunol 1996; 26:1974-1977.
19. Litwin V, Gumperz J, Parham P, et al. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994; 180:537-543.
20. Gumperz JE, Litwin V, Phillips JH, et al. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995; 181:1133-1144.
21. + HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008; 112:435-443.
22. Stern M, Ruggeri L, Capanni M, et al. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood 2008; 112:708-710.
23. Gumperz JE, Barber LD, Valiante NM, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol 1997; 158:5237-5241.
24. O'Connor GM, Guinan KJ, Cunningham RT, et al. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 2007; 178:235-241.
25. + HLA-B with KIR3DL1. J Immunol 2008; 181:6293-6300.
26. Kurago ZB, Lutz CT, Smith KD, Colonna M. NK cell natural cytotoxicity and IFN-g production are not always coordinately regulated: engagement of DX9 KIR+ NK cells by HLA-B7 variants and target cells. J Immunol 1998; 160:1573-1580.
27. Vivian JP, Duncan RC, Berry R, et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011; 479:401-405.
28. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Variable NK cell receptors exemplified by human KIR3DL1/S1. J Immunol 2010; 187:11-19.
29. O'Connor GM, Yamada E, Rampersaud A, et al. Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1. J Immunol 2011; 187:2162-2171.
30. Martin MP, Gao X, Lee J-H, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
31. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633-645.
32. Thananchai H, Gillespie G, Martin MP, et al. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007; 178:33-37.
33. Takamiya Y, Sakaguchi T, Miwa K, Takiguchi M. Role of HLA-B*5101 binding nonamer peptides in formation of the HLA-Bw4 public epitope. Int Immunol 1996; 8:1027-1034.
34. Peruzzi M, Parker KC, Long EO, Malnati MS. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J Immunol 1996; 157:3350-3356.
35. Peruzzi M, Wagtmann N, Long EO. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLAB*2705. J Exp Med 1996; 184:1585-1590.
36. Fadda L, O'Connor GM, Kumar S, et al. Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J Virol 2011; 85:5970-5974.
37. O'Connor GM, Vivian JP, Widjaja JM, et al. Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. J Immunol 2014; 192:2875-2884.